Connor, Clark & Lunn Investment Management (CC&L)
PRVB

Connor, Clark & Lunn Investment Management (CC&L)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,864
Closed -$157K – 1272
2021
Q4 		$157K Sell
27,864
-20,619
-43% -$131K ﹤0.01% 1004
2021
Q3 		$310K Buy
+48,483
New +$312K ﹤0.01% 868

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PRVB Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 27,864 shares — an estimated $157K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PRVB in Q3 2021 and held it in 2 quarters. The position peaked at $310K in Q3 2021. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 27,864 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $157K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Provention Bio, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Provention Bio, Inc. Common Stock position peaked at $310K in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.